sinecatechins topical (Rx)

Brand and Other Names:Veregen
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

topical ointment

  • 15%

Condylomata Acuminatum

Indicated for topical treatment of external genital and perianal warts (condylomata acuminatum) in immunocompetent patients

Immunocompetent patients: Apply topically q8hr; use approximately a 0.5-cm strand of ointment for each external genital or perianal wart; continue treatment until complete clearance of all warts, but not to exceed 16 wk

Immunosuppressed patients: Safety and efficacy not established

Safety and efficacy not established

Next:

Adverse Effects

>10%

Erythema (70%)

Pruritus (69%)

Burning (67%)

Pain/discomfort (56%)

Erosion/ulceration (49%)

Edema (45%)

Induration (35%)

Vesicular rash (20%)

1-10%

Phimosis (3%)

Inguinal lymphadenitis

Desquamation (5%)

Discharge (3%)

Bleeding (2%)

Scarring (1%)

Irritation (1%)

Rash (1%)

< 1%

Facial rash

Vulvitis

Eczema

Hyperesthesia

Pigmentation changes

Discoloration

Necrosis

Papules

Pelvic pain

Perianal infection

Previous
Next:

Warnings

Contraindications

Hypersensitivity

Cautions

Not evaluated for urethral, intravaginal, cervical, rectal, or intra-anal HPV disease and should not be used to treat these conditions

Avoid application to open wounds, eyes, and nose

Wash hands before and after application

Severe reactions reported more commonly in women

Severe reactions may require treatment interruption or discontinuation

Avoid sexual contact while ointment is on skin

Ointment not intended for internal use (avoid applying to open wounds)

Avoid exposure of treated areas to UV-light

Continue treatment until all warts have been cleared; not to exceed 16 weeks

Previous
Next:

Pregnancy & Lactation

Pregnancy

There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

Animal data

  • In animal reproduction studies, drug did not cause malformations, but did affect the developing fetus in presence of maternal toxicity when given to pregnant rabbits and rats by intravaginal or systemic routes of administration during period of organogenesis; available data do not allow calculation of relevant comparisons between systemic exposure of drug observed in animal studies to systemic exposure that would be expected in humans after topical use

Lactation

There are no data on presence of sinecatechins in human or animal milk, effects on breastfed child, or on milk production; after topical application, product concentrations in plasma are low and therefore concentrations in human breast milk are likely to be low

Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breast-fed child from product or from underlying maternal condition

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Botanical for topical use consisting of extract from green tea leaves; mode of action unknown, but does elicit antioxidant activity in vitro

Pharmacokinetics

Absorption: Minimal

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.